Market expectations30 Jun 2024 17:57
As expected the share price is a slave to investor emotion, post results. The material sales uncertainty is fully expected but changes nothing commercially. Having led two successful start ups, I would be surprised if the suppliers weren't insisting on proforma terms (ie cash before delivery) as credit insurance would be at best a nominal value. Having qualified accounts won't therefore change anything in this respect.
I was reassured that the Board's expectation of 2024 and 2025 financial performance are unchanged from those described in the May fund raising (which were were the low case from the April RNS):
Quarterly Sales/Effective capacity revenue
Q2-24 - £4m / £7m
Q3-24 - £4.8m / £7m
Q4-24 - £5.8m (EBITDA breakeven on a quarterly basis) / £9m
Q1-25 - £7m (cash flow neutrality on a quarterly basis) / £10m
Manufacturing Yield
Q2-24 - 83%
Q3-24 - 85%
Q4-24 - 86%
According to my workings, cash headroom on this basis would be £2m in Q1-25, which would be the low point (assuming invoice discounting financed 2025 sales growth) and normal 30 days terms with all suppliers were negotiated.
In this game of building businesses, success breeds success as new arrangements that positively affect cash flow can be negotiated eg change of terms of trade with supply base, invoice financing to facilitate aggressive sales growth etc.
I believe that management have all the tools/staff and facilities they need to turn this into a profitable business using existing funds. Despite calls otherwise, they should also let the COO crack on with his job, without the distraction of being given a board position for the next year.
I look forward to tracking the quarterly updates vs the OO document KPIs by way of a scorecard on progress, starting with the H2 update pre-AGM. If they hit these then the share price will re-rate significantly.